Small Nebraska startup hopes to challenge Pfizer, Merck in pneumococcal vaccine race

31 Jan 2023
endpts.com
VaccinePhase 3Executive Change
A new biotech out of Lincoln, NE, launched Monday aiming to tackle what it says is an unaddressed need in the pneumococcal vaccine space. Aeolian Biotech debuted with a promise to fill the gaps left by currently approved pneumococcal vaccines using its own shot. The company aims to accomplish this with its sole candidate, iPCV22, which was developed by former Wyeth/Pfizer researchers Jack Love and Bruce Forrest, who worked on the Prevnar project and are now Aeolian co-founders. “They left after Prevnar 13,” Aeolian CEO Tyler Martin told Endpoints News . “This was their idea. And they filed the patent together. They now are my head of regulatory [affairs] and my CSO. And that’s where we got the patents; we exclusively license it from them. They had filed it and maintain prosecution themselves as individual people.” Martin added the company is primarily focusing on raising a Series A right now, which he hopes will be completed later this year. It should be enough for three years of runway, Martin said, and take Aeolian through its proof-of-concept data. If everything goes according to plan, iPCV22 would protect against 95% of disease-causing serotypes, compared to just an average of 60% with approved vaccines like Prevnar 20. The biotech is also going up against Merck’s V116 shot, currently in Phase III testing, which covers about 85-90% of disease-causing serotypes. Martin came to Aeolian after leaving Adjuvance Technologies’ CEO post in March 2022, though he remains on the board of directors. Adjuvance announced last April it was seeking a strategic merger or sale .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.